These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 3439205)

  • 1. [Treatment of peripheral arterial occlusive disorders with rheologically active measures].
    Turowski A; Schmidt HH; Sternitzky R
    Z Arztl Fortbild (Jena); 1987; 81(17):883-8. PubMed ID: 3439205
    [No Abstract]   [Full Text] [Related]  

  • 2. [Blood rheology in peripheral occlusive disease. Effects of hemodilution and pentoxifylline].
    Angelkort B
    Wien Med Wochenschr; 1986; 136 Spec No():29-35. PubMed ID: 3548089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Whole blood viscosity in patients with acral arterial occlusive diseases and their modification by rheologically active drugs].
    Runge E; Thiele P
    Z Gesamte Inn Med; 1987 Mar; 42(5):137-41. PubMed ID: 3590891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of I.V. application of pentoxifylline on the viscoelasticity of blood in patients with peripheral vascular disorders.
    Chmiel H; Anadere I; Heimburg P
    Ric Clin Lab; 1981; 11 Suppl 1():189-96. PubMed ID: 7188108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hyper- or isovolemic hemodilution in patients with stage II peripheral arterial occlusive disease].
    Kiesewetter H; Jung F; Blume J; Spitzer S; Birk A
    Acta Med Austriaca; 1991; 18 Suppl 1():23-7. PubMed ID: 1719729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Iso- and hypervolemic hemodilution with hydroxyethyl starch (HES 200/.05 10%) in patients with II b peripheral arterial occlusive disease].
    Kiesewetter H; Blume J; Jung F; Spitzer S; Gerhards M; Waldhausen P; Wenzel E
    Wien Med Wochenschr; 1989 Sep; 139(17):396-401. PubMed ID: 2480029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hemodilution in peripheral arterial occlusive disease--study comparing 3 different variants of hemodilution].
    Weidinger P; Bilek M; Tekusch A
    Vasa Suppl; 1990; 30():137-8. PubMed ID: 2075564
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effects of pentoxifylline on blood viscosity and peripheral hemodynamics in patients with peripheral occlusive arteriopathies].
    Guerrini M; Pecchi S; Rossi C; Cappelli R; Pieragalli D; Acciavatti A
    Ric Clin Lab; 1981; 11 Suppl 1():265-79. PubMed ID: 7188114
    [No Abstract]   [Full Text] [Related]  

  • 9. [Therapeutic efficacy of pentoxifylline in peripheral artery diseases: its clinical value].
    Benignetti G; Fabbri F; Benvenuti C
    Clin Ter; 1983 Feb; 104(4):297-304. PubMed ID: 6861465
    [No Abstract]   [Full Text] [Related]  

  • 10. [Therapeutic consequences of hemorheologic research].
    Ernst E
    Wien Med Wochenschr; 1989 Dec; 139(24):569-80. PubMed ID: 2696217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Blood rheology in chronic arterial occlusive disease as influenced by vasodilators (author's transl)].
    Störmer B; Kleinschmidt F; Loose D; Kremer K
    Dtsch Med Wochenschr; 1978 Apr; 103(16):694-8. PubMed ID: 639718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Kinetic effects of 6% hydroxyethyl starch 200.000/0.6-0.66 in hypervolemic hemodilution].
    Költringer P; Langsteger W; Lind P; Klima G; Pierer G; Reisecker F; Eber O
    Acta Med Austriaca; 1991; 18 Suppl 1():20-2. PubMed ID: 1719728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemorheologic conditions in patients with cerebrovascular disease altered by treatment with pentoxifylline.
    Ott E; Lechner H
    Ric Clin Lab; 1981; 11 Suppl 1():253-6. PubMed ID: 7188113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Walk training and drug therapy in peripheral arterial occlusive disease. A randomized, prospective, placebo-controlled double-blind study].
    Kiesewetter H; Blume J; Jung F; Gerhards M; Leipnitz G
    Dtsch Med Wochenschr; 1987 May; 112(22):873-8. PubMed ID: 3556133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hypervolemic hemodilution with medium molecular-weight hydroxyethyl starch: effect of duration of administration on viscoelasticity of blood in IIa and IIb peripheral arterial occlusive disease].
    Költringer P; Langsteger W; Lind P; Klima G; Pierer G; Reisecker F; Eber O
    Acta Med Austriaca; 1991; 18 Suppl 1():45-7. PubMed ID: 1719731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Induced hemodilution as a new concept in the therapy of peripheral circulatory disorders].
    Rieger H
    Internist (Berl); 1982 Jul; 23(7):375-82. PubMed ID: 7049999
    [No Abstract]   [Full Text] [Related]  

  • 17. [Hemorheologic therapy in peripheral arterial occlusive disease].
    Kiesewetter H; Jung F
    Fortschr Med; 1984 Oct; 102(37):921-4. PubMed ID: 6500451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of chronic occlusive arterial disease with pentoxifylline: changes in clinical and haemodynamic parameters.
    Schweiger H; Ortmeier CJ
    Pharmatherapeutica; 1989; 5(5):298-304. PubMed ID: 2526340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hemodilution in peripheral arterial occlusive disease. Placebo controlled randomized double-blind study with hydroxyethyl starch or dextran].
    Ernst E; Kollar L; Matrai A
    Acta Med Austriaca; 1991; 18 Suppl 1():27-9. PubMed ID: 1719730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypervolumetric hemodilution with HES 100/0.5 10% in patients with peripheral arterial occlusive disease (Fontaine, stage II): an open clinical and pharmacological phase IV study.
    Koscielny J; Latza R; Pruss A; Kiesewetter H; Jung F; Meier C; Schimetta W
    Clin Hemorheol Microcirc; 2000; 22(1):53-65. PubMed ID: 10711822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.